Literature DB >> 6500079

Correlation and comparison of Nb2 lymphoma cell bioassay with radioimmunoassay for human prolactin.

M G Subramanian, N J Spirtos, K S Moghissi, D M Magyar, M F Hayes, R R Gala.   

Abstract

Serum samples from groups of men and women with normal and elevated prolactin (PRL) levels were assayed by radioimmunoassay (RIA) and by Nb2 lymphoma cell bioassay (BA) for the presence of PRL. Because the Nb2 lymphoma cells respond to both PRL and growth hormone, BA for PRL activity was carried out before and after neutralization of growth hormone in the serum samples. There were excellent correlations between RIA and BA both in euprolactinemic (r = 0.7587; P less than 0.002) and hyperprolactinemic (r = 0.9558; P less than 0.001) subjects. On an absolute basis, RIA and BA values were similar in the euprolactinemic group (6.6 +/- 0.8 versus 6.2 +/- 1.0), whereas in the hyperprolactinemic group, RIA values were significantly higher than the BA results (89.41 +/- 22.4 versus 62.1 +/- 21.2). The two assay systems also appeared to correlate better in women who were hyperprolactinemic, with obvious menstrual cycle disturbances, than in hyperprolactinemic women without menstrual cycle disturbances.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6500079     DOI: 10.1016/s0015-0282(16)48258-0

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  3 in total

1.  Human follicular fluid: prolactin is biologically active and ovum fertilization correlates with estradiol concentration.

Authors:  M G Subramanian; A G Sacco; K S Moghissi; D M Magyar; M F Hayes; D M Lawson; R R Gala
Journal:  J In Vitro Fert Embryo Transf       Date:  1988-06

2.  Bioactivity and immunoreactivity of rat pituitary prolactin submitted to various extraction procedures.

Authors:  M I Prada; H A Pasolli; A I Torres; A Aoki
Journal:  J Endocrinol Invest       Date:  1995-05       Impact factor: 4.256

3.  Prolactin bioassay and hyperprolactinemia.

Authors:  C A Peabody; P N Schultz; M D Warner; I G Worsley; H G Friesen; N A Samaan
Journal:  J Endocrinol Invest       Date:  1992 Jul-Aug       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.